Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates
- PMID: 25814063
- PMCID: PMC4565490
- DOI: 10.1126/science.aaa4919
Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates
Abstract
Zaire ebolavirus is the causative agent of the current outbreak of hemorrhagic fever disease in West Africa. Previously, we showed that a whole Ebola virus (EBOV) vaccine based on a replication-defective EBOV (EBOVΔVP30) protects immunized mice and guinea pigs against lethal challenge with rodent-adapted EBOV. Here, we demonstrate that EBOVΔVP30 protects nonhuman primates against lethal infection with EBOV. Although EBOVΔVP30 is replication-incompetent, we additionally inactivated the vaccine with hydrogen peroxide; the chemically inactivated vaccine remained antigenic and protective in nonhuman primates. EBOVΔVP30 thus represents a safe, efficacious, whole-EBOV vaccine candidate that differs from other EBOV vaccine platforms in that it presents all viral proteins and the viral RNA to the host immune system, which might contribute to protective immune responses.
Copyright © 2015, American Association for the Advancement of Science.
Figures



Comment in
-
New Advances in the Effort against Ebola.Cell Host Microbe. 2015 May 13;17(5):545-7. doi: 10.1016/j.chom.2015.04.015. Cell Host Microbe. 2015. PMID: 25974296
-
Viral infections: New options to fight Ebola.Nat Rev Drug Discov. 2015 Jun;14(6):385. doi: 10.1038/nrd4642. Nat Rev Drug Discov. 2015. PMID: 26027535 No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical